Treatment
Injectable agent
In the tuberculosis context, it refers to aminoglucosides such as amikacin, capreomycin, kanamycin, or streptomycin, previously considered to be key MDR-TB regimen components (the term as used here does not include the second-line TB drugs imipenem and meropenem that are also given by injection).
Early bactericidal activity
The ability of anti-tuberculosis drugs or treatments to reduce the burden of M. tuberculosis in sputum specimens collected overnight from people with laboratory-confirmed pulmonary tuberculosis during the first 14 days of therapy.
